Stock Report: XenoPort Inc. (XNPT) Report Updated: Jun 17, 2013 | Print This Page

XenoPort, Inc., a biopharmaceutical company, focuses on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. The company’s lead product includes Gabapentin Enacarbil, a transported prodrug of Gabapentin for the treatment of moderate-to-severe primary restless legs syndrome (RLS) in adults. It markets Gabapentin Enacarbil under the Horizant name in the United States, as well as under the Regnite name in Japan and five other Asian countries. The company is also developing Arbaclofen Placarbil, which is in Phase III clinical trial for the treatment of spasticity in patients with MS, stroke and cerebral palsy, and spinal cord injury; XP21279, a transported prodrug of Levodopa, which is in Phase II clinical trial for the treatment of Parkinson’s disease; and XP23829, a novel prodrug of Monomethyl Fumarate that is in preclinical stage for the potential treatment for relapsing-remitting MS. It has strategic alliances with Astellas Pharma Inc. and Glaxo Group Limited to develop and commercialize Gabapentin Enacarbil. XenoPort, Inc. was founded in 1999 and is based in Santa Clara, California.